BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 37035197)

  • 21. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
    Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
    Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
    Xu W; Yang S; Tam CS; Seymour JF; Zhou K; Opat S; Qiu L; Sun M; Wang T; Trotman J; Pan L; Gao S; Zhou J; Zhou D; Zhu J; Song Y; Hu J; Feng R; Huang H; Su D; Shi M; Li J
    Adv Ther; 2022 Sep; 39(9):4250-4265. PubMed ID: 35900694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
    Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
    Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
    O'Brien SM; Brown JR; Byrd JC; Furman RR; Ghia P; Sharman JP; Wierda WG
    Front Oncol; 2021; 11():720704. PubMed ID: 34858810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
    Zhou K; Wang T; Pan L; Xu W; Jin J; Zhang W; Hu Y; Hu J; Feng R; Li P; Liu Z; Liu P; Jing H; Gao S; Zhang H; Yu K; Wang Z; Zhu X; Sun Z; Li F; Yan D; Weng J; Fu L; Wang L; Salmi T; Wu K; Qiu L
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38888616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
    Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
    Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.
    Sawalha Y; Bond DA; Alinari L
    Onco Targets Ther; 2020; 13():6573-6581. PubMed ID: 32753893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
    Alsuhebany N; Pan C; Holovac E; Do B; McBride A
    Blood Lymphat Cancer; 2023; 13():67-76. PubMed ID: 38034984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
    Bose P; Gandhi V
    Fac Rev; 2021; 10():22. PubMed ID: 33718939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.
    Lu J; Do B; Primeaux B
    J Oncol Pharm Pract; 2024 Feb; ():10781552241232331. PubMed ID: 38356268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zanubrutinib: past, present, and future.
    Tam CS; Muñoz JL; Seymour JF; Opat S
    Blood Cancer J; 2023 Sep; 13(1):141. PubMed ID: 37696810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib in CLL/SLL: From bench to bedside (Review).
    Zi F; Yu L; Shi Q; Tang A; Cheng J
    Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of acalabrutinib in adults with chronic lymphocytic leukemia.
    Fakhri B; Andreadis C
    Ther Adv Hematol; 2021; 12():2040620721990553. PubMed ID: 33613932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
    Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.